Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

ABVC Biopharma Inc

ABVC ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$0.98

▼ -2.97%

Market Cap $26.16M · Vol 17.76K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$26.16M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

39.02

Momentum

Beta

0.44

vs Market

52W High

$3.39

71.09% below

52W Low

$0.71

38.63% above

Volume

17.76K

Avg 17.46K

P/B

4.80

Price-to-book

ROE

N/A

Return on equity

Free Float

81.91%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, ABVC Biopharma Inc (ABVC) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ABVC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-6.67%

+2.07%

-45.56%

-10.09%

YTD

-53.99%

-67.33%

+20.99%

-95.55%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-8,376,960.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-58.41% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	4.80
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	26.69M

Technical Indicators

50-Day SMA	$0.99
200-Day SMA	$1.37
RSI (14)	39.02
Beta	0.44
52-Week High	$3.39
52-Week Low	$0.71

Volume Today	17.76K
Avg Daily Volume (30D)	17.46K
Relative Volume	1.02x
Volatility (10D)	48.63
Volatility (30D)	91.36
Free Float	81.91%

Analyst Consensus

N/A

Current Price $0.98

Mean Target N/A

52W Low$0.71 52W High$3.39

Current

Target

$0.71 $3.39

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001SMCS49

ISINUS00091F3047

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +1.14% ARGX.BR argenx SE -0.37% ARGX argenx SE -0.69% 2269.HK WuXi Biologics (Cayman) Inc. +1.56% INSM Insmed Incorporated -6.56%

Company Profile

ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.